GE Healthcare Life Sciences Announces New US Headquarters in Massachusetts - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GE Healthcare Life Sciences Announces New US Headquarters in Massachusetts


GE Healthcare Life Sciences has announced that it will open a 160,000-sq ft facility in Marlborough, Mass., as the new headquarters for its US operations.  The $21 million facility will employ more than 500 GE Healthcare Life Sciences employees.

The company reports that the investment will transform a currently unoccupied space into state-of-the-art labs, customer application facilities, and office space to complement GE Healthcare Life Sciences’ existing manufacturing capability in Westborough, Mass. The facility will consolidate GE Healthcare Life Sciences’ US East Coast presence. When fully operational, the facility will bring more than 220 highly qualified new job opportunities to the area, including highly skilled positions such as lab technicians, biologists, medical doctors, process engineers, and customer service representatives.

GE Healthcare Life Sciences’ $4 billion business has more than 11,500 employees in more than 100 countries. The new US headquarters will house employees from across the Life Sciences business, including its research, bioprocessing, medical imaging, in vitro diagnostics, and services segments. Recruitment has begun with the site scheduled to open in Spring 2015.

 Source: GE Healthcare Life Sciences

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here